MX2020012596A - Procesos e intermedios para preparar un medicamento. - Google Patents

Procesos e intermedios para preparar un medicamento.

Info

Publication number
MX2020012596A
MX2020012596A MX2020012596A MX2020012596A MX2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A
Authority
MX
Mexico
Prior art keywords
sup
intermediates
processes
medicament
preparing
Prior art date
Application number
MX2020012596A
Other languages
English (en)
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020012596A publication Critical patent/MX2020012596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulga un proceso para preparar los siguientes compuestos: (ver Fórmulas) en donde R1, R1a y R2a son como se han definido en la memoria descriptiva, así como también un proceso para preparar otros intermedios que pueden ser útiles para sintetizar productos posteriores, especialmente compuestos que son útiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib; también se divulgan otros procesos, otros intermedios y compuestos per se.
MX2020012596A 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento. MX2020012596A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17

Publications (1)

Publication Number Publication Date
MX2020012596A true MX2020012596A (es) 2021-02-09

Family

ID=51535892

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012731A MX2015012731A (es) 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento.
MX2020012596A MX2020012596A (es) 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012731A MX2015012731A (es) 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento.

Country Status (19)

Country Link
EP (1) EP2970291B1 (es)
JP (1) JP6777398B2 (es)
KR (2) KR102377688B1 (es)
CN (2) CN112608298A (es)
AU (2) AU2014230935A1 (es)
BR (1) BR112015021856A2 (es)
CA (1) CA2901510C (es)
DK (1) DK2970291T3 (es)
EA (1) EA201591685A1 (es)
ES (1) ES2924193T3 (es)
HR (1) HRP20220628T1 (es)
HU (1) HUE058914T2 (es)
LT (1) LT2970291T (es)
MX (2) MX2015012731A (es)
MY (1) MY194905A (es)
PE (1) PE20151652A1 (es)
SG (2) SG11201507595XA (es)
SI (1) SI2970291T1 (es)
WO (1) WO2014139970A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
TWI748941B (zh) * 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
LV15201B (lv) * 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
WO2019027860A1 (en) 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
BR112021022347A2 (pt) * 2019-05-21 2022-01-04 Janssen Pharmaceutica Nv Processos e intermediários para a preparação de um inibidor de btk
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
EP2201840B1 (en) * 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2954900A1 (en) * 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2590982B1 (en) * 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
AU2013299557B2 (en) * 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
AP2015008381A0 (en) * 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
EP2970291A1 (en) 2016-01-20
WO2014139970A1 (en) 2014-09-18
DK2970291T3 (da) 2022-08-01
LT2970291T (lt) 2022-06-10
HUE058914T2 (hu) 2022-09-28
EA201591685A1 (ru) 2016-01-29
KR20150132172A (ko) 2015-11-25
HRP20220628T1 (hr) 2022-06-24
SG11201507595XA (en) 2015-10-29
JP2016510779A (ja) 2016-04-11
JP6777398B2 (ja) 2020-10-28
CA2901510C (en) 2022-11-29
EP2970291B1 (en) 2022-05-11
KR20210123429A (ko) 2021-10-13
PE20151652A1 (es) 2015-11-12
MY194905A (en) 2022-12-22
MX2015012731A (es) 2016-02-18
SI2970291T1 (sl) 2022-07-29
AU2014230935A1 (en) 2015-09-03
AU2018204086A1 (en) 2018-06-28
ES2924193T3 (es) 2022-10-05
KR102377688B1 (ko) 2022-03-22
BR112015021856A2 (pt) 2017-07-18
AU2018204086B2 (en) 2020-03-12
SG10201809696UA (en) 2018-11-29
KR102311329B1 (ko) 2021-10-14
CN105026400A (zh) 2015-11-04
CA2901510A1 (en) 2014-09-18
CN112608298A (zh) 2021-04-06

Similar Documents

Publication Publication Date Title
MX2020012596A (es) Procesos e intermedios para preparar un medicamento.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
TN2014000427A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
MX365315B (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12015502000A1 (en) Processes and intermediates for preparing a medicament
IN2013CH04314A (es)
IN2013MU02059A (es)
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation